GlassScriptPhysician profile
Alexander Antoni Slota
NPI 1225514102
$851.84
in general payments reported to CMS, 2019-2025
21 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.96 · 2020: $77.03 · 2021: $116 · 2022: $88.58 · 2024: $243 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440 · Education: $78.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.18 |
| Education | $78.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $116.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $109.69 | 2019-2025 | Opdivo, Krazati |
| Sumitomo Pharma America, INC. | $105.79 | 2025 | Orgovyx |
| Beigene USA, INC. | $88.58 | 2022 | |
| Gilead Sciences, INC. | $77.03 | 2020 | |
| Pfizer INC. | $47.14 | 2024-2025 | |
| Daiichi Sankyo INC. | $30.86 | 2024 | Injectafer |
| Novocure INC. | $29.69 | 2024 | Optune Lua (Novottf-200t), Optune |
| Janssen Biotech, INC. | $24.71 | 2025 | Rybrevant |
| Abbvie INC. | $24.26 | 2024 | |
| Tempus Ai, INC | $23.78 | 2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $22.53 | 2024 | Krazati |
| Bard Peripheral Vascular, INC. | $21.02 | 2025 | Pleurx |
| Novartis Pharmaceuticals Corporation | $20.20 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.36 | 2024 | Libtayo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.93 | 2024 | Keytruda, Lynparza |
| Jazz Pharmaceuticals INC. | $17.07 | 2025 | |
| Lilly USA, LLC | $15.12 | 2024 | Jaypirca, Verzenio |
| Array Biopharma INC | $14.05 | 2024 | Mektovi, Xalkori, Braftovi |
| Genzyme Corporation | $13.89 | 2025 | |
| Springworks Therapeutics, INC. | $13.77 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Slota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.